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OBJECTIVES: To analyse the effectivity and safety of
tacalcitol in real daily conditions. METHODS: An epi-
demiological, observational, prospective and multicenter
study of a cohort of patients with mild to moderate Pso-
riasis vulgaris has been performed. Treatment with tacal-
citol ointment (4mg/g) was prescribed. Anthropometric
and demographic characteristics of patients were re-
corded in addition to percentage of affected area and pre-
vious and current treatments. A lesion was selected as
target for evaluation, of symptoms (erythema, desqua-
mation and thickness) by a scale from 0 (absent) to 4
(maximum intensity of symptom). At follow-up (30 and
60 days) symptomatology and appearance of adverse
events were evaluated. Psoriasis Area Severity Index
(PASI) was calculated. RESULTS: Eight hundred twenty-
one patients with mild to moderate Psoriasis vulgaris,
(45.67% were men and 45.33% were women, mean age
43.59 ± 15,48 years) were included. After 2 months of
treatment, patients showed a decrease of mean percent-
age of affected area of 7.83 ± 12.3 (from 15.97% ±
16.02% to 8.14 ± 10.59). PASI decreased from 10.11 ±
7.89 to 3.00 ± 3.79 (p < 0.01). Percentage of patients
without symptoms increased up to 85.44% for erythema,
93.11% for desquamation and 96.16% for thickness. Six
adverse events were reported (1% of sample). Seventy-
eight percent of investigators and 80% of patients 
evaluated effectivity of treatment as satisfactory. CON-
CLUSIONS: Tacalcitol was effective in symptomatic
treatment of psoriasis. Treatment achieved improvement
on affected area and intensity of symptoms as well. Excel-
lent tolerability of tacalcitol was corroborated by the low
rate of adverse events reported.
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MANAGEMENT AND SOCIO ECONOMIC
IMPACT OF ATOPIC DERMATITIS (AD) IN
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OBJECTIVE: To evaluate the management and socio-
economic consequences of AD on patients and parents of
children with AD in France. METHODS: Retrospective
crossectional study in a representative national sample of
patients suffering from AD has been conducted between
March and June 2002. One hundred children and 90
adults have been recruited from a representative panel of
4012 individuals of the general population. Data was col-
lected on aspects of the disease, medical resource use and
Quality of Life (QoL). RESULTS: On average, the mean
time spent with AD during the last year was 131 days;
26% of patients reported having symptomatic AD all the
time, the other patients had 5.5 ﬂares on average. Mean
duration of the last ﬂare in the overall sample was 21
days. Ninety percent of the patients consulted a physician
during the last year for their AD. Sixty-two percent of
adults had usually seen a general practitioner (GP) and/or
a dermatologist (57%). Fourty-one percent of adults and
42% of children had seen a GP exclusively. None of the
patients interviewed were hospitalized for AD during the
last 12 months. We estimated the annual medical and
non-medical cost of AD in France at €128 million per
year, physician consultations accounting for 59% of this
cost. AD impairs signiﬁcantly the patients and parents
QoL. Adults declared having no relieve from it (40%),
being worried about their appearance (36%), ﬁnding it
hard to relax (33%), having no self-conﬁdence (24%).
Parents reported having no control over the disease
(53%), are worried about the future of their children
(17%) and 13% said AD created much tension in the
family. CONCLUSION: This unprecedented study shows
that AD signs and symptoms affect patients for one-third
of the year on average, producing a signiﬁcant socio-
economic burden on the patients and their family
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OBJECTIVES: Topical steroids are the corner-stone of
current treatment for atopic dermatitis (AD), a chronic
ﬂuctuating inﬂammatory skin disease. However, steroids
carry a risk of local and systemic side effects limiting their
long term use and effectiveness. The objective was to
assess the incremental cost-effectiveness ratio (ICER) of
the new topical immunomodulator Tacrolimus in moder-
ate to severe AD. Tacrolimus has shown signiﬁcant clin-
ical improvement, maintained with long term intermittent
treatment up to four years. METHODS: A Markov
model was developed in MS-Excel. Model health states
represent severe, moderate, mild, and virtually cured AD
as deﬁned by the Eczema Area and Severity Index (EASI).
Based on prevalence data, 82% start with moderate, 18%
with severe AD. The model simulates monthly severity
ﬂuctuations. Transitions among health states were calcu-
lated from two 1-year observational trials (Tacrolimus 
n = 93, current care n = 120). Tacrolimus consumption
was obtained from the clinical trial, other resource utili-
sation from a two-round Delphi consensus panel (n = 8).
Unit costs from the Belgian health care payers perspective
were applied. Effects are expressed in “disease controlled
days”, deﬁned as days with mild or virtually cured AD.
The time horizon was from 1 (basecase) to 3 years.
